Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Published:2017-06 Issue:6 Volume:18 Page:779-791
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Coleman Robert L,Brady Mark F,Herzog Thomas J,Sabbatini Paul,Armstrong Deborah K,Walker Joan L,Kim Byoung-Gie,Fujiwara Keiichi,Tewari Krishnansu S,O'Malley David M,Davidson Susan A,Rubin Stephen C,DiSilvestro Paul,Basen-Engquist Karen,Huang Helen,Chan John K,Spirtos Nick M,Ashfaq Raheela,Mannel Robert S

Funder

National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office

Gynecologic Oncology Group Statistical Office

NRG Oncology

NRG Operations

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nature Rev Clin Oncol,2013

2. Whole-genome characterization of chemoresistant ovarian cancer;Patch;Nature,2015